Lilly’s Lechleiter ‘Cautiously Optimistic’ On U.S. Tax Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
Timing could be right for changes to the U.S. corporate tax policy, Lilly CEO said during third quarter earning call; the problem, however, is working out the details.
You may also be interested in...
Emerging Markets Earnings: Eli Lilly Finds Room To Grow In Asia, Brazil
Eli Lilly finds a bright spot in emerging markets for the third quarter with insulin a prime driver of growth.
Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.